[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Polytechnic Institute of Porto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100650865","combining-noninvasive-brain-stimulation-and-augmented-reality-based-dichoptic-therapy-for-treating-amblyopic-adults-100650865",false,"NCT07752433","Combining Noninvasive Brain Stimulation and Augmented Reality-based Dichoptic Therapy for Treating Amblyopic Adults","NiBS4Vision","Inclusion Criteria:\n\n* Age between 18 and 35 years.\n* Diagnosis of anisometropic amblyopia.\n* Unilateral amblyopia with an interocular difference of at least 2 lines in best-corrected visual acuity, with visual acuity worse than 20\u002F32 in the worse-seeing eye.\n\nExclusion Criteria:\n\n* Any type of amblyopia other than anisometropic amblyopia.\n* Bilateral amblyopia.\n* Ophthalmological or neuro-ophthalmological disease other than amblyopia.\n* Neurological disease.\n* Chronic pharmacological treatment.\n* Presence of an implanted medical device.\n* Any ocular surgery or treatment within the previous year.\n* Significant ocular media opacities.\n* Previous treatment with transcranial direct current stimulation or another non-invasive brain stimulation technique.\n* Pregnancy or planning to become pregnant during the study period.\n* Inability to provide informed consent.\n* History of head trauma, seizures, or frequent headaches.\n* Electrical or electronic implants, such as a cardiac pacemaker.\n* Metallic objects or implants in the head, except dental implants.","ALL","18 Years","40 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether adding noninvasive brain stimulation to augmented reality-based vision therapy can improve vision in adults aged 18 to 40 years with unilateral anisometropic amblyopia, commonly called \"lazy eye.\" Anisometropic amblyopia develops during childhood when the two eyes have different focusing powers and the brain relies more on one eye than the other.\n\nThe main questions this study aims to answer are:\n\n* Does active high-definition transcranial direct current stimulation (HD-tDCS) improve best-corrected visual acuity in the amblyopic eye and depth perception more than sham stimulation?\n* Does the combined treatment improve contrast sensitivity, suppression between the eyes, and measures of retinal and visual brain function?\n\nAll participants will receive the same augmented reality-based dichoptic therapy. This therapy presents different visual information to each eye and lowers the contrast seen by the stronger eye. This gives the weaker, amblyopic eye a visual advantage and encourages both eyes to work together while participants carry out normal daily activities.\n\nDuring the first 2 weeks, participants will also receive either active HD-tDCS or sham stimulation immediately before the augmented reality therapy. Active HD-tDCS delivers a weak electrical current through small electrodes placed on the scalp. Sham stimulation uses the same equipment and procedures, but the current is applied only briefly at the beginning. Comparing the two groups will help researchers determine whether active brain stimulation provides additional benefits beyond those of augmented reality therapy alone.\n\nParticipants will:\n\n* Complete 40-minute augmented reality therapy sessions four times per week for 10 weeks.\n* Receive eight 20-minute sessions of active or sham HD-tDCS during the first 2 weeks, immediately before the augmented reality therapy.\n* Attend assessment visits before treatment, after 2 weeks, and after 10 weeks. These visits will include vision tests, retinal imaging, tests of retinal function, and brain imaging.",[27,28],"Amblyopia","Anisometropic Amblyopia",[30,28,31,32,33,34,35,36,37,38],"Adult Amblyopia","Dichoptic Therapy","Augmented Reality","Transcranial Direct Current Stimulation","High-Definition Transcranial Direct Current Stimulation","Noninvasive brain stimulation","Visual rehabilitation","Binocular vision","Neuroplasticity","RECRUITING","2026-08-03",{"date":42,"type":43},"2026-08-07","ACTUAL",{"date":45,"type":43},"2025-05-01",{"date":47,"type":21},"2028-04-30",{"name":49,"class":50},"Polytechnic Institute of Porto","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":51},"100629461","iprgc-as-a-potential-biomarker-for-predicting-transcranial-magnetic-stimulation-treatment-response-in-major-depressive-disorder-100629461","NCT07474974","ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder","Illuminating Depression: ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder","BRIGHT","Inclusion Criteria:\n\n* Diagnosis of MDD, confirmed via the structured clinical interview;\n* TRD type;\n* Age between 18-65 years;\n* Visual acuity of 20\u002F32 or better.\n\nExclusion Criteria:\n\n* Prior rTMS treatment;\n* Contraindications for TMS;\n* Psychiatric disorders other than MDD;\n* Systemic diseases affecting the eyes (e.g., diabetes mellitus);\n* Ocular conditions;\n* Head injuries causing loss of consciousness;\n* Current or past alcohol\u002Fsubstance dependence within 6 months;\n* Neurodegenerative diseases;\n* Major neurological illnesses;\n* Use of medications affecting iris mechanics or the autonomic nervous system.","65 Years",{"count":62,"type":21},44,[24],"This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in treatment-resistant depression (TRD). We also aim to assess the impact of TMS treatment on RGCs and ipRGCs in TRD patients, investigating associations with clinical improvements and cognitive status. A clinical trial involving 44 patients with treatment-resistant depression (TRD) will be conducted. All participants will receive rTMS targeting the dorsolateral prefrontal cortex (DLPFC). Data will be collected pre- and post-intervention, as well as at a 2-month follow-up, using multiple outcome measures, including the post-illumination pupil response (PIPR). The project seeks to confirm the effectiveness of TMS and the potential of RGCs\u002FipRGCs as predictors of treatment response, thereby facilitating the development of personalized treatment strategies for TRD patients undergoing rTMS therapy.",[66,67],"Depression - Major Depressive Disorder","Treatment Resistant Depression",[69,70,71,72,73],"Major Depressive Disorder","Repetitive Transcranial Magnetic Stimulation","Retinal Ganglion Cells","ipRGCs","Treatment-resistant depression",{"date":75,"type":43},"2026-08-06",{"date":77,"type":43},"2026-03-15",{"date":79,"type":21},"2027-07-31",{"name":49,"class":50},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":51},"100629480","expert-validation-of-an-autonomous-personalized-physical-activity-algorithm-100629480","NCT07475221","Expert Validation of an Autonomous Personalized Physical Activity Algorithm","Validation of a Personalized Physical Activity Algorithm Via Modified e-Delphi (InnovaMotion Project)","APPA e-Delphi","Inclusion Criteria\n\n* Experts in Physical Activity and Exercise with recognized scientific or professional experience and a relevant doctoral degree.\n* Availability to complete two rounds of the online modified Delphi questionnaire.\n* Willingness to participate in an online focus group if consensus is not reached.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria\n\n* Individuals unable to provide informed consent.\n* Individuals without access to a computer, smartphone, tablet, or other internet-enabled device necessary to complete the online survey.",{"count":90,"type":21},9,"OBSERVATIONAL","This study aims to validate a personalized physical activity algorithm for risk screening and individualized exercise prescription using a modified online Delphi process. International experts in physical activity and exercise will evaluate the algorithm's components over two rounds of questionnaires, with consensus defined as ≥70% agreement. If needed, a focus group will resolve any remaining disagreements. Validation of this algorithm may support safer, more effective autonomous exercise, promoting adherence, improved health outcomes, and population-level benefits.",[94],"Experts in Physical Activity Prescription and Risk Health Screening",[96,97,98,99,100,101,102,103],"eDelphi","physical activity","Modified Delphi","Digital Health","Expert Consensus","Exercise Prescription","screening","health risk stratification","2026-03-14",{"date":106,"type":43},"2026-03-17",{"date":108,"type":43},"2026-03-10",{"date":110,"type":21},"2026-12",{"name":49,"class":50},""]